The education library
Dianabol: methandienone, historical research and health risks
Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.
Names and scope
Dianabol is commonly associated with methandienone, also written metandienone or methandrostenolone. These names appear across different decades of clinical literature. They should not be confused with methasterone, a different steroid that also appears in liver-injury searches. Evidence about one molecule cannot simply be relabelled as evidence about another.
This profile examines what historical human studies can tell us, what they cannot establish, and why Canadian regulatory context matters. It does not provide instructions for nonmedical use. The most defensible educational approach is to acknowledge measured biological effects while separating them from claims that the drug improves overall health or is safe.
History: clinical research and sporting use are different stories
The literature includes controlled investigations of osteoporosis as well as experiments involving athletes. A historical experiment is evidence that a question was studied; it is not, by itself, evidence of an approved indication. A complete account of original marketing authorization and withdrawal history still requires archived regulatory records. This review deliberately leaves those dates unresolved rather than repeating conflicting timelines from commercial websites.
A 1977 double-blind study included 26 postmenopausal women with osteoporosis. Sixteen completed 26 months. Among completers, total body calcium increased by 2% in the treated group and decreased by 3% with placebo. The investigators interpreted the findings primarily as prevention of bone loss; an increase above starting bone mass was less certain. This is a meaningful historical signal, but it is a small study with substantial attrition and a bone-mineral outcome rather than clear proof of fracture prevention. Chesnut and colleagues, 1977
A 1983 trial studied 327 older adults receiving combinations of calcium, vitamin D, methandienone or placebos. The abstract described changes in biochemical and muscle-related measures, but the higher fracture incidence in the placebo group was not statistically significant. That distinction matters: promising intermediate measurements should not be rewritten as a demonstrated reduction in broken bones. Full-report review is needed to understand the combined treatment groups and safety findings. Inkovaara and colleagues, 1983
These studies do not establish a present-day role ahead of modern osteoporosis treatments. A clinical recommendation would require current comparative evidence, regulatory status and an individualized benefit–risk assessment.
What the athlete studies found
A 1975 double-blind crossover trial enrolled 13 experienced male weightlifters. Improvements were greater during methandienone exposure than placebo, but body weight and systolic blood pressure also rose, and three participants withdrew because of adverse effects. The investigators thought water retention contributed to weight gain. Both sides of that finding belong in an accurate account: a performance signal was accompanied by harm, even in a small, short experiment. Freed and colleagues, 1975
A later crossover experiment in seven male weightlifters investigated body nitrogen and potassium as well as weight, muscle size and performance. Nitrogen changes suggested the gain was not simply intracellular fluid. However, the proportions did not resemble an ordinary gain of normal muscle or lean tissue. This is a warning against turning a scale change into a precise claim about new functional muscle. The sample was too small to establish reliable long-term benefit or safety. Body-composition experiment, 1981
Neither trial supplies a predictable personal outcome. Their small samples, older measurement methods, short observation periods and specific training populations limit generalization. They also do not answer what happens to health years later.
Hormonal effects and non-instructional pharmacology
An anabolic effect does not mean the body's own hormone production is increased. In a human study of 16 trained athletes, average testosterone fell by about 69% during exposure, while luteinizing hormone and follicle-stimulating hormone also fell substantially. These hormones are part of the signalling system linking the brain, pituitary and testes. The study supports suppression of this system; it does not establish an individual recovery timeline or a way to prevent suppression. Holma and Adlercreutz, 1976
Mechanistic research in rats examined muscle responses alongside reproductive hormone signalling and myostatin-related pathways. It found tissue-specific effects and evidence of suppressed endogenous testosterone production. These findings help researchers ask biological questions, but rat muscles and hormonal responses cannot be used to predict a person's benefit, fertility or adverse-event probability. Mosler and colleagues, 2012
The important distinction is between an observed tissue-building effect and healthy endocrine function. One can occur alongside disruption of the other.
Liver, kidney and other organ risks
A 2011 case report described a man with cholestatic jaundice, acute kidney injury and acute pancreatitis following reported methandrostenolone use. Imaging and tissue investigations supported injury in multiple organs. A case report cannot calculate how often this happens or establish every causal detail, but it documents a serious clinical event that should not be dismissed because controlled trials were small. Case report, 2011
A 1999 report described severe cholestasis and kidney failure after combined methandienone and stanozolol exposure. Because more than one substance was involved, it cannot isolate methandienone's contribution. It is relevant to the hazards of complex exposure, not a basis for assigning a precise risk percentage to either drug. Habscheid and colleagues, 1999
Health Canada's advisory associates anabolic steroid use with liver damage, heart attacks, strokes, reduced fertility, arterial disease, virilization and male breast changes. The blood-pressure increase in the 1975 trial and hormone suppression in the 1976 study provide separate compound-specific observations, but they do not quantify every long-term risk. Health Canada advisory, updated 2022
Interactions and populations requiring further review
A complete, contemporary compound-specific interaction assessment was not verified for this summary. It would be misleading to copy a complete interaction list from another steroid's label and imply it has been verified for methandienone.
The older studies summarized here do not establish safety in pregnancy, children, people with cardiovascular or liver disease, or those taking multiple medicines. Lack of a study in a group is an evidence gap, not reassurance. Likewise, the human hormone study does not measure the probability or duration of fertility problems in an individual. These limitations are central to interpreting the evidence.
Canadian regulatory context
The Health Canada advisory updated in June 2022 explicitly stated that methandrostenolone was not approved by Health Canada. That is a dated official statement, not a completed October 2026 search of every product record. The dated advisory is not presented as a live October 2026 product-database result. Official advisory
Regulatory authorization, controlled-substance scheduling and a product being advertised online are separate questions. This review provides no purchasing or import guidance, and the presence of historical trials does not resolve current legal or clinical access.
Common claims that need qualification
- Weight gain is not a direct measurement of healthy muscle gained.
- A change in bone mineral measurements does not automatically mean fewer fractures.
- A drug can produce an anabolic response while suppressing endogenous reproductive hormones.
- A small study with reversible short-term side effects cannot establish long-term safety.
- “Studied in medicine” and “currently approved for this use in Canada” are different claims.
Additional bone evidence identified during cross-checking
A 1981 double-blind randomized study followed methandrostenolone versus placebo for 24 months. Body potassium increased mainly early in treatment, but sustained bone-mass improvement was not readily demonstrable with the methods used. This qualifies the more encouraging 1977 findings: historical studies did not establish a consistent bone benefit, and neither a body-composition change nor an isolated bone measurement proves fracture prevention. Full reports should be compared before drawing a stronger conclusion. Aloia and colleagues, 1981